EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Relevance of Lenvatinib in Advanced Hepatocellular Carcinoma: Insights from a Prospective Observational Cohort in South India

Joe Jose, Shibu V Ignatious, Thattungal Manoharan Anoop

Drugs - Real World Outcomes · 2026-06 · 13 (2) · 253-264

DOI: 10.1007/s40801-026-00554-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs - Real World Outcomes, online erschienen am 20.04.2026. Verfasst von Joe Jose und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Regional Cancer Centre, Trivandrum, Kerala, 695011, India. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NATCO.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Medical Oncology, Regional Cancer Centre, Trivandrum, Kerala, 695011, India.
  • Department of Medical Oncology, Regional Cancer Centre, Trivandrum, Kerala, 695011, India. dranooptm@gmail.com.

Förderung

  • NATCO

Zitieren

APA

Jose, J., Ignatious, S. V., & Anoop, T. M. (2026). The Relevance of Lenvatinib in Advanced Hepatocellular Carcinoma: Insights from a Prospective Observational Cohort in South India. Drugs - Real World Outcomes, 13(2), 253-264. https://doi.org/10.1007/s40801-026-00554-w

Vancouver

Jose J, Ignatious SV, Anoop TM. The Relevance of Lenvatinib in Advanced Hepatocellular Carcinoma: Insights from a Prospective Observational Cohort in South India. Drugs - Real World Outcomes. 2026;13(2):253-264. doi:10.1007/s40801-026-00554-w

BibTeX
@article{Jose2026,
  author = {Jose, Joe and Ignatious, Shibu V and Anoop, Thattungal Manoharan},
  title = {The Relevance of Lenvatinib in Advanced Hepatocellular Carcinoma: Insights from a Prospective Observational Cohort in South India},
  journal = {Drugs - Real World Outcomes},
  year = {2026},
  volume = {13},
  number = {2},
  pages = {253--264},
  doi = {10.1007/s40801-026-00554-w}
}
Kostenlos starten →